226 Chapter 7 39. Prat M, Crepaldi T, Pennacchietti S, Bussolino F, Comoglio PM. Agonistic monoclonal antibodies against the Met receptor dissect the biological responses to HGF. J Cell Sci 1998;111 ( Pt 2):237-47. 40. Athauda G, Giubellino A, Coleman JA, Horak C, Steeg PS, Lee MJ, et al. c-Met ectodomain shedding rate correlates with malignant potential. Clin Cancer Res 2006;12:4154-62. 41. Crepaldi T, Prat M, Giordano S, Medico E, Comoglio PM. Generation of a truncated hepatocyte growth factor receptor in the endoplasmic reticulum. J Biol Chem 1994;269:1750-5. 42. De Herdt MJ, Koljenovic S, van der Steen B, Willems SM, Noorlag R, Nieboer D, et al. MET ectodomain shedding is associated with poor disease-free survival of patients diagnosed with oral squamous cell carcinoma. Mod Pathol 2020;33:1015-32. 43. Deheuninck J, Foveau B, Goormachtigh G, Leroy C, Ji Z, Tulasne D, et al. Caspase cleavage of the MET receptor generates an HGF interfering fragment. Biochem Biophys Res Commun 2008;367:573-7. 44. Kang JY, Dolled-Filhart M, Ocal IT, Singh B, Lin CY, Dickson RB, et al. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res 2003;63:1101-5. 45. Merlin S, Pietronave S, Locarno D, Valente G, Follenzi A, Prat M. Deletion of the ectodomain unleashes the transforming, invasive, and tumorigenic potential of the MET oncogene. Cancer Sci 2009;100:633-8. 46. De Herdt MJ, Willems SM, van der Steen B, Noorlag R, Verhoef EI, van Leenders GJ, et al. Absent and abundant MET immunoreactivity is associated with poor prognosis of patients with oral and oropharyngeal squamous cell carcinoma. Oncotarget 2016;7:13167-81. 47. De Herdt MJ, Koljenovic S, van der Steen B, Willems SM, Wieringa MH, Nieboer D, et al. A novel immunohistochemical scoring system reveals associations of C-terminal MET, ectodomain shedding, and loss of E-cadherin with poor prognosis in oral squamous cell carcinoma. Hum Pathol 2020;104:42-53. 48. Nath D, Williamson NJ, Jarvis R, Murphy G. Shedding of c-Met is regulated by crosstalk between a G-protein coupled receptor and the EGF receptor and is mediated by a TIMP-3 sensitive metalloproteinase. J Cell Sci 2001;114:1213-20. 49. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 2004;4:361-70. 50. Lui VW, Thomas SM, Zhang Q, Wentzel AL, Siegfried JM, Li JY, et al. Mitogenic effects of gastrin-releasing peptide in head and neck squamous cancer cells are mediated by activation of the epidermal growth factor receptor. Oncogene 2003;22:6183-93. 51. Kornfeld JW, Meder S, Wohlberg M, Friedrich RE, Rau T, Riethdorf L, et al. Overexpression of TACE and TIMP3 mRNA in head and neck cancer: association with tumour development and progression. Br J Cancer 2011;104:13845. 52. Shao Y, Sha XY, Bai YX, Quan F, Wu SL. Effect of A disintegrin and metalloproteinase 10 gene silencing on the proliferation, invasion and migration of the human tongue squamous cell carcinoma cell line TCA8113. Mol Med Rep 2015;11:212-8. 53. Arnold L, Enders J, Thomas SM. Activated HGF-c-Met Axis in Head and Neck Cancer. Cancers (Basel) 2017;9. 54. McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, Lamb J, et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A 2007;104:19936-41. 55. Bardelli A, Corso S, Bertotti A, Hobor S, Valtorta E, Siravegna G, et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov 2013;3:658-73.
RkJQdWJsaXNoZXIy MTk4NDMw